Explore News By Topic


New Study indicates 18 months of androgen deprivation therapy may be optimal for locally advanced prostate cancer

Results from the RADAR clinical trial presented at the 2018 ASCO Genitourinary Cancer Symposium indicate that 18 months of ADT could very likely become the new standard of care. The RADAR trial demonstrated that 18 months of androgen deprivation therapy (ADT) is significantly better than 6 months of ADT at... Read More


Prostate Cancer Loves Couch Potatoes

Hey, guys:  If you think exercise is just about pumping iron and getting big traps, six-pack abs and “gun show” biceps, your prostate would like to disagree. To your prostate, how ripped or shredded you are is not nearly as important as your cardiovascular health. Now, you may be wondering,... Read More


BREAKING NEWS: FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer

February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC).  This clinical setting is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More


Blood Profiling Atlas in Cancer Consortium (BloodPAC) Announces Milestone in Accelerating Development of Liquid Biopsy for Cancer: Initial Release of Open Data

CHICAGO – Exactly one year after its establishment as an independent non-profit, The Blood Profiling Atlas in Cancer Consortium (BloodPAC) announced the public release and accessibility of an initial dataset. The dataset resides in the BloodPAC Data Commons and was developed to deepen the understanding of an individual patient’s cancer... Read More


Two new treatments have been found for prostate cancer patients who previously had no effective treatment options

Over the course of prostate cancer progression, there can come a time during which the cancer is progressing, but there are no treatments known to improve survival.  One of these “empty spaces” is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More


FDA approves Abiraterone + Prednisone for Earlier Treatment of Metastatic Prostate Cancer

Back in June, we told you about the early results of the LATITUDE clinical trial, presented at the 2017 ASCO conference.   The study indicated that giving abiraterone in combination with low-dose prednisone to men who were just starting ADT delayed cancer progression by an average of 18 months.  The study... Read More


Statins and Prostate Cancer: The Search for the Magic Bullet

Do statins lower your risk of getting aggressive prostate cancer?  Well, they may. Study after study hints at a tantalizing connection between taking these cholesterol-lowering drugs and protection from getting lethal prostate cancer. But an actual magic pill guaranteed to do this just keeps hovering just over the horizon, like... Read More


The Prostate Cancer Foundation Honors Family And Caregivers During February With The True Love Contest

SANTA MONICA, CA, January 31, 2018 – Starting February 1st, the Prostate Cancer Foundation (PCF) will kick-off a month-long TRUE Love contest that honors family and caregivers for their tireless work in caring for their loved ones living with prostate cancer. TRUE is a tribute to the unsung heroes –... Read More


The Prostate Cancer Foundation Awards Unprecedented Number of New Research Grants

SANTA MONICA, Calif., January 23, 2018 – Celebrating its 25th year as the global leader in driving cutting-edge research leading to treatments and cures for prostate cancer, the Prostate Cancer Foundation (PCF) today announced it has awarded an additional $8 million in research funding to eight new 2017 PCF Challenge... Read More


Cleveland Clinic researchers find new gene variant linked to deadly prostate cancer

Jan. 17 2018, Cleveland: Cleveland Clinic researchers have confirmed for the first time a mechanistic link between the gene HSD17B4 and deadly, treatment-resistant prostate cancer. The research, led by Nima Sharifi, M.D., Cleveland Clinic Lerner Research Institute, Department of Cancer Biology, shows that men who lack a certain subtype of... Read More